Opsumit (Macitentan) Patent Expiration, LOE Window & CMS Spending

Opsumit (Macitentan) by Johnson & Johnson: FDA Orange Book core substance LOE 2026-06-05 (last listed 2029-10-18), 12 AB generics, $1.45B 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN204410 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2026-06-05
Last Listed Patent or Exclusivity Date2029-10-18
Orange Book Patents (*PED Extensions)10 patents (5 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$1.45B
2024 Medicare Part D Spend$1.23B
2024 Medicaid Spend$221.2M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 19.8% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.